Aspire Biopharma Holdings Inc. (NASDAQ: ASBP) announced its board of directors authorized a $5 million share repurchase program, according to a shareholder letter from Chief Executive Officer Kraig Higginson.

The biopharmaceutical company recently completed the second tranche of a preferred stock private placement that generated approximately $21 million in net proceeds. The company stated it has returned to full compliance with Nasdaq's stockholders' equity requirements.

Aspire filed four provisional patent applications in early 2026 for sublingual powder formulations of generic drugs including Alprazolam, Clopidogrel, Ondansetron, and Meclizine. The filings occurred between January and February 2026 and expand the company's drug delivery technology portfolio.

The company plans to file a New Drug Application for its lead candidate, a high-dose sublingual aspirin, by the end of 2026 through the 505(b)(2) regulatory pathway. The formulation is designed to inhibit platelet aggregation in under two minutes for emergency cardiac care.

On April 16, 2026, Aspire announced a binding letter of intent to acquire Dura Driver Control Systems (DCS) for $30 million in cash. DCS reported over $200 million in 2025 revenue and more than $22 million in adjusted EBITDA, according to unaudited figures. The automotive supplier operates 11 manufacturing facilities worldwide and holds over 310 patents.

The acquisition is supported by a $22.5 million financing commitment and is not expected to require additional equity raises, according to the company. DCS serves over 50 customers with average relationships spanning 28 years.

Aspire's consumer supplement subsidiary BUZZ BOMB launched 50mg caffeine stick packs and entered a strategic partnership with EoS Fitness, which operates more than 225 gym locations. The partnership provides access to EoS's affiliate program that generated over 80 million impressions in 2025.